House Sunscreen Bill Advances, But TEA Review Deadlines In Question
This article was originally published in The Rose Sheet
The House Energy and Commerce Health subcommittee unanimously advanced the Sunscreen Innovation Act to full committee June 19, but provisions in the original bill seeking a tight timeline for FDA’s review of sunscreen ingredient time-and-extent applications are now in limbo, according to the Public Access to Sunscreens coalition of stakeholders.
You may also be interested in...
The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.
As European industry’s concerns grow about “politicization” of regulatory programs, the United States-Mexico-Canada Agreement’s cosmetics annex directs regulatory authorities pursuing new rules to give due consideration to scientific and technical guidance documents developed through international collaboration.
Canada has agreed to end its practice of quarantining and retesting certain cosmetic-OTC drug products from the US, as part of a cosmetics-specific annex to the United States-Mexico-Canada Agreement. “There will be a very significant and immediate benefit to US exporters of OTC products to Canada,” a Personal Care Products Council exec said.